Alumis Inc. (ALMS) saw its stock price surge 15.55% on Friday, closing at $24.15 on the Nasdaq. The move came on heavy trading volume of approximately 2.25 million shares, more than double the stock's average daily volume of 1.01 million shares. The rally pushed the company's market capitalization to $3.08 billion, bringing the stock closer to its 52-week high of $30.60.
What Drove the Rally?
The sharp increase was fueled by a combination of factors, including strong analyst support and positive data from the company's late-stage psoriasis trials. Alumis is developing envudeucitinib, an oral TYK2 inhibitor targeting tyrosine kinase 2, an enzyme involved in immune signaling and inflammatory diseases. In March, the company reported that its Phase 3 ONWARD1 and ONWARD2 trials in plaque psoriasis achieved PASI 90 responses—meaning a 90% improvement on the Psoriasis Area and Severity Index—of 68.0% and 62.1% at 24 weeks. Complete skin clearance, measured by PASI 100, was achieved in 41.0% and 39.5% of patients at the same time point.
Analyst Sentiment Remains Bullish
Wall Street analysts have maintained a positive outlook on Alumis. According to Benzinga, the stock has a consensus Buy rating with an average price target of $36.73. Recent analyst calls include Chardan with a Buy rating and a $40 target, Wells Fargo with an Overweight rating and a $51 target, and Guggenheim with a Buy rating and a $34 target. These targets suggest significant upside from the current price, but the stock is still considered a high-risk biotech investment.
Key Milestones Ahead
Investor attention is now focused on Alumis' upcoming clinical and regulatory milestones, rather than Friday's price move. The company expects topline data from its potentially pivotal Phase 2b LUMUS trial in systemic lupus erythematosus (SLE) in the third quarter of 2026. Additionally, Alumis plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration for its psoriasis treatment in the fourth quarter of this year. CEO Martin Babler stated, “We remain on track for our NDA submission in the fourth quarter of this year.”
Financial Position and Risks
As of March 31, Alumis reported $569.5 million in cash, cash equivalents, and marketable securities. The company believes this cash runway will cover operating costs and capital spending into the fourth quarter of 2027, allowing it to reach several important readouts and regulatory events. However, the company remains unprofitable, posting a net loss of $93.1 million in the first quarter. Alumis has warned that it expects to continue incurring significant losses and does not anticipate any revenue from product sales unless it obtains regulatory approval and successfully commercializes its products. The company also has a $300 million at-the-market equity program in place, which could lead to shareholder dilution if exercised.
Market Context and Outlook
While Friday's rally was impressive, it places Alumis firmly in the high-risk biotech category rather than representing a clear value opportunity. The stock's valuation is heavily dependent on the success of the upcoming lupus trial, a successful NDA submission, FDA approval, and the company's ability to compete in the immunology space. For cautious investors, the sharp price increase raises the risk profile until the next major clinical or regulatory update.
